BACKGROUND: Sodium polystyrene sulfonate (Kayexalate; Sanofi-Aventis, Paris, France)
is a cation-exchange resin routinely used in the management of hyperkalemia. However, its …

Hyperkalaemia is common in patients with chronic kidney disease (CKD), in part because of
the effects of kidney dysfunction on potassium homeostasis and in part because of the …

5.2. 1. Ocena funkcji skurczowej lewej komory...................................... 1052 5.2. 2. Ocena
funkcji rozkurczowej lewej komory...................................... 1052 5.2. 3. Ocena funkcji prawej …

Potassium disorders are common in patients with kidney disease, particularly in patients
with tubular disorders and low glomerular filtration rate. A multidisciplinary group of …

Irrespective of the cause of cardiac arrest, early recognition and calling for help, including
appropriate management of the deteriorating patient, early defibrillation, high-quality …

Hypokalemia and hyperkalemia are common electrolyte disorders caused by changes in
potassium intake, altered excretion, or transcellular shifts. Diuretic use and gastrointestinal …

Worldwide, approximately 300 million people of all ages and ethnic backgrounds have
asthma. 296 T he worldwide prevalence of asthma symptoms ranges from 1 to 18% of the …

Las guías de práctica clínica (GPC) tienen como objetivo reunir y evaluar toda la evidencia
relevante disponible durante el proceso de elaboración sobre un tema particular para …

Introduction Severe hyperkalemia, with potassium (K+) levels≥ 6.5 mEq/L, is a potentially
life-threatening electrolyte imbalance. For prompt and effective treatment, it is important to …

Treatment options for hyperkalemia have not changed much since the introduction of the
cation exchange resin, sodium polystyrene sulfonate (Kayexalate, Covis Pharmaceuticals …